文献速递甲状腺与颈部外科

T1/T2淋巴结阴性高细胞型甲状腺乳头状癌的手术治疗:腺叶切除是否足够?

Surgical management of T1/T2 node-negative papillary thyroid cancer with tall cell histology: Is lobectomy enough?
PubMed 文献 · Surgery · 2022-10-17

该研究比较了T1/T2淋巴结阴性高细胞型甲状腺乳头状癌患者行腺叶切除与经典型甲状腺乳头状癌患者的预后。结果显示两组10年总生存率(P=.56)和局部区域无复发生存率(P=.52)无显著差异,高细胞组无复发。提示T1淋巴结阴性高细胞型肿瘤行腺叶切除可获得与经典型相当的肿瘤学结局。

要点

  • T1/T2淋巴结阴性高细胞型甲状腺乳头状癌行腺叶切除后10年总生存与经典型无显著差异。
  • 高细胞组疾病特异生存率和局部或中央区淋巴结无复发生存率均为100%。
  • 高细胞型肿瘤定义为 tall cells ≥30%。

核心结论

  • T1淋巴结阴性高细胞型甲状腺乳头状癌行甲状腺腺叶切除可满意管理,肿瘤学结局与经典型甲状腺乳头状癌相当。

研究设计与样本

  • 回顾性队列研究,评估1985年至2015年在该机构手术治疗的well-differentiated thyroid cancers。
  • 比较行腺叶切除的淋巴结阴性T1/T2高细胞型肿瘤患者与经典型甲状腺乳头状癌患者,排除早期计划完成性甲状腺切除术者。

主要发现

  • T1/T2 N0X疾病行甲状腺腺叶切除者中,高细胞型70例(15%),经典型429例(23%)。
  • 10年总生存率无显著差异(P = .56),局部区域无复发生存概率无显著差异(P = .52)。
  • 两组疾病特异生存率和局部或中央区淋巴结无复发生存概率均为100%。
  • 9例甲状腺乳头状癌发生对侧叶肿瘤,5例发生侧颈转移,高细胞组未见复发。

关键数值与推荐

  • 高细胞型肿瘤定义为 tall cells ≥30%。
  • 10年总生存率比较P = .56,局部区域无复发生存概率比较P = .52。

临床怎么用

  • 对于T1/T2淋巴结阴性高细胞型甲状腺乳头状癌,可考虑行甲状腺腺叶切除而非更激进手术。

局限性

  • 回顾性单中心研究,样本量有限,高细胞组仅70例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The tall cell variant of papillary thyroid carcinoma has traditionally been treated more aggressively than classic papillary thyroid carcinoma. However, this may not be justified in patients with T1/T2 tall cell variant node-negative tumors. METHODS: We evaluated well-differentiated thyroid cancers treated surgically between 1985 and 2015 at our institution. We compared patients undergoing lobectomy for node-negative T1/T2 tall cell variant tumors with the same cohort with classic papillary thyroid carcinoma. Patients who underwent early planned completion thyroidectomy were excluded. Tall cell variant tumors were defined as those with ≥30% tall cells. Survival and recurrence outcomes were determined by the Kaplan-Meier method and groups compared using the log-rank test. RESULTS: Thyroid lobectomy was performed for T1/T2 N0X disease in 70 (15%) tall cell cases and 429 (23%) classic papillary thyroid carcinoma cases. There was no significant difference in 10-year overall survival (P = .56) or locoregional recurrence-free probability (P = .52). Disease-specific survival and local or central nodal recurrence-free probability were 100% in both groups. In 9 papillary thyroid carcinoma cases, subsequent contralateral lobe tumors developed, and in 5, lateral neck metastases developed. No recurrences were seen in the tall cell group. CONCLUSION: T1 node-negative tumors with tall cell histology can be satisfactorily managed with thyroid lobectomy, with equivalent oncological outcomes to classic papillary thyroid carcinoma.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Woods RSR, Fitzgerald CWR, Valero C, et al. Surgical management of T1/T2 node-negative papillary thyroid cancer with tall cell histology: Is lobectomy enough? Surgery. 2022. PMID: 36257862. doi:10.1016/j.surg.2022.05.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。